PFIZER share price target 2026

BazaarBaazi does not publish a SEBI-registered price target on PFIZER. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.

The BazaarBaazi Crack Score for PFIZER is 55 out of 100 as of 21 Jul 2026, a constructive reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.

Strike-level option inventory for PFIZER is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.

PFIZER sits in Healthcare (mid cap), indicative market cap ~21,013 cr (indicative), ISIN INE182A01018. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on Pfizer Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on PFIZER is mixed, published in Systematic Read on 21 Jul 2026.

On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, Pfizer Limited sits in the Near-perfect tier with a setup score of 69/100 (technical 83, fundamental 67). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.

BazaarBaazi indexes 1 PFIZER earnings call going back to 2020-08-31, latest 2020-08-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.

Pfizer Limited reported a net profit of Rs 200 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -39.6% year on year. The figure is from the company's official NSE filing.

Pfizer Limited reported revenue of Rs 629 cr for Q4 FY26. That is +6.3% year on year. The figure is from the company's official NSE filing.

BazaarBaazi gives Pfizer Limited's Q4 FY26 result a Result Pulse of 48 out of 100, with a verdict of Mixed. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.

Pfizer Ltd's two most material recent disclosures are a dividend dated 17 Jul 2026, "Dividend - Rs 75 Per Share", and a disclosure dated 17 Jul 2026, "The Exchange has sought clarification from Pfizer Limited…". Both link to the company's own official filing on the BazaarBaazi stock page.

Yes. Pfizer Ltd filed a dividend disclosure on 17 Jul 2026, filed as "Dividend - Rs 75 Per Share". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.

Pfizer Ltd's most recent board-meeting disclosure on record dated 12 May 2026 reads "Notice of Annual General Meeting to be held on July 28, 2026". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.